Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $16.75 and last traded at $16.76, with a volume of 311398 shares trading hands. The stock had previously closed at $17.48.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on KLRA. Wall Street Zen downgraded shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Jefferies Financial Group began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price for the company. Evercore began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating for the company. TD Cowen began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target on the stock. Finally, William Blair initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Kailera Therapeutics has a consensus rating of “Buy” and a consensus price target of $42.75.
Read Our Latest Report on KLRA
Kailera Therapeutics Price Performance
Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last released its quarterly earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.
Kailera Therapeutics Company Profile
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.
Recommended Stories
- Five stocks we like better than Kailera Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Kailera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kailera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
